MedTrace Logo

Hellenic Evaluation of the Long-Term Safety and Efficacy of NalIriFOx as a 1st-line Therapy in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

NCT07723261 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2026-07-24

No results posted yet for this study

Summary

This is multicenter, prospective, open label, non-interventional study that will collect real-world data (RWD) on the clinical efficacy and safety of NalIriFOx as a first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).

Conditions

  • Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Sponsors & Collaborators

  • Hellenic Cooperative Oncology Group

    lead OTHER

Principal Investigators

  • Athina Christopoulou, MD, PhD · Oncology Unit, General Hospital of Patras "Agios Andreas"

  • George Papaxoinis, MD · 2nd Dept of Medical Oncology, "Agios Savvas" Anti Cancer Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-30
Primary Completion
2029-03-30
Completion
2029-03-30

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07723261 on ClinicalTrials.gov